5d 1m 3m 1y 5y 10y
There is research on this stock available only to PRO subscribers.
There are no Transcripts on HART.
Harvard Apparatus Regenerative Technology to Present at 2nd Annual Regen Med Investor Day in New York CityBusiness Wire (Feb 27, 2014)
Business Wire (Feb 24, 2014)
Business Wire (Feb 5, 2014)
Business Wire (Jan 17, 2014)
HART vs. ETF Alternatives
Currently, there's no company description for HART.
Country: United States
Wednesday, Mar 59:24 AM|Wednesday, Mar 59:24 AM| Comment!
Monday, Nov 42013, 8:45 AM
Monday, Nov 42013, 8:45 AM| 6 Comments
- Harvard Bioscience (HBIO) is off 16% premarket after completing a spin-off of its regenerative medicine device subsidiary.
- Harvard Apparatus Regenerative Technology now trades on the Nasdaq under the ticker HART.
- HBIO shareholders got one share of HART for every share of HBIO they owned as of October 21.
- HBIO now calls itself a "pure-play global developer, manufacturer and marketer of a broad range of tools to advance life science research." (PR)
- CEO Jeffrey Duchemin has been appointed President and Director, replacing David Green who is now HART's President.